The week that Kevin T. Conroy took over as CEO of Exact Sciences Corp. in 2009, the molecular-diagnostics company got a warning from the Nasdaq that it faced delisting if its market capitalization didn’t improve. Its efforts to develop a noninvasive test for colon cancer had stalled and its stock was trading at around $1.. Mr. Conroy, a lawyer who had helmed another company’s development of a cervical cancer test, rebuilt Exact Sciences from the ground up. He joined forces with a Mayo Clinic scientist doing similar research;...
  